Clinical Trial Update: GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating GCS-100LE in combination with etoposide and dexamethasone for relapsed or refractory diffuse large B-cell lymphoma was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Etoposide (Etoposide)
• GCS-100LE (GCS-100LE)

Snippet

Sponsor: La Jolla Pharmaceutical Company | Conditions: Diffuse Large B-cell Lymphoma | Phase 1, Phase 2 | Status: WITHDRAWN